DevvStream

SKYE BIOSCIENCE (OTCMKTS: SKYE) STOCK QUOTE

Last Trade: US$0.02 -0.0013 -7.98
Volume: 1,161,047
5-Day Change: -1.00%
YTD Change: -1.00%
Market Cap: US$3.750M

LATEST NEWS FROM SKYE BIOSCIENCE

Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, announced today that it will present a corporate overview at the RHK 2022 Disruptive Growth Conference being held December 5-6, 2022, at the offices of Reed Smith in New York City. Punit Dhillon, Chief Executive Officer and Chair, will present on Monday,... Read More
Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical company developing proprietary, synthetic cannabinoid derivatives, has submitted an Investigational New Drug application ("IND") to the U.S. Food and Drug Administration for SBI-100 Ophthalmic Emulsion ("SBI-100 OE), which it is developing for the treatment of glaucoma. Once opened, the IND will allow the Company to conduct clinical trials in the... Read More
Recruitment for cohort 1 has begun Clinical trial material manufactured and shipped to Australia San Diego, California--(Newsfile Corp. - November 16, 2022) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, has initiated screening for its first-in-human Phase 1 trial of SBI-100 Ophthalmic Emulsion ("SBI-100... Read More
VANCOUVER, BC , Nov. 11, 2022 /CNW/ - Emerald Health Sciences Inc. (" Sciences ") announces that on November 10, 2022 , it beneficially owns and controls the following securities of Skye Bioscience, Inc. (the " Issuer "): (A) 111,387,251 common shares (the " Shares ") of the Issuer; (B) a convertible loan in the outstanding amount of US$2,014,500 (the " Convertible Loan ") convertible into 5,036,250 Shares at a price of... Read More
Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, has been advised by its contract manufacturer (“CMO”) that it has completed the production of SBI-100 Ophthalmic Emulsion (“SBI-100 OE”) for Skye’s Phase 1 clinical trial. The final drug product will be released and available for clinical use in October,... Read More
Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, announces that it has filed its definitive proxy statement related to its special meeting to be held online on September 30, 2022. Stockholders as of August 29 th , 2022, will receive a definitive proxy statement, voting card, and voting instructions by mail or... Read More
San Diego, California, Aug. 19, 2022 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, reports that the shareholders of Emerald Health Therapeutics, Inc. ("Emerald" or the "Company") (CSE: EMH; OTCQB: EMHTF) today approved the proposed plan of arrangement (the "Arrangement") with Skye, with... Read More
Skye advances Phase 2 clinical development plans alongside Phase 1 clinical development Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, has selected NextPharma as its contract manufacturing organization (“CMO”) for its Phase 2 clinical trial material. NextPharma is a leading European pharmaceutical contract... Read More
Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, has been advised by its contract manufacturer (“CMO”) of its Phase 1 clinical trial material that a now-resolved cyber-attack on the CMO’s computer systems as well as a planned annual maintenance shutdown will result in a delay in completing production of Skye’s... Read More
Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, has received regulatory approval to begin its first-in-human Phase 1 clinical study of SBI-100 Ophthalmic Emulsion ("SBI-100 OE") from the Australian Human Research Ethics Committee ("HREC"). SBI-100 OE is a patented drug representing a new class of therapeutics... Read More
New collaborations focused on building library of novel cannabinoid derivatives and small molecules capable of modulating endocannabinoid system Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing proprietary, synthetic cannabinoid derivatives to treat glaucoma and other diseases with significant unmet needs, has signed new research agreements with the University of Eastern... Read More
Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical company developing proprietary, synthetic cannabinoid derivatives to treat glaucoma and other diseases with significant unmet need, announced today that it will be presenting a corporate overview at the LD Micro 12th Annual Invitational being held in-person at the Four Seasons Westlake Village, California, June 7-9, 2022. Punit Dhillon, Chief... Read More
Arrangement is expected to fund Skye’s proprietary synthetic cannabinoid-derivative therapeutic initially targeting glaucoma for first Phase 2 clinical study planned to start later in 2022 Preclinical studies have demonstrated potential advantages of Skye’s unique, patent-protected therapeutic drug, SBI-100 Ophthalmic Emulsion, compared to the standard of care Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye”) and Emerald Health... Read More
Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing proprietary, synthetic cannabinoid derivatives to treat glaucoma and other diseases with significant unmet need, announced that the peer-reviewed journal International Journal of Pharmaceutics published preclinical data demonstrating stronger and longer-lasting reduction of intraocular pressure (IOP) when Skye’s proprietary... Read More
Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing proprietary, synthetic cannabinoid derivatives to treat glaucoma and other diseases with significant unmet need, has retained CMAX Clinical Research (“CMAX”) to facilitate enrollment of and drug administration to healthy volunteers for Skye’s Phase 1 study of its lead product candidate, SBI-100 Ophthalmic Emulsion (“SBI-100... Read More
Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need, has entered into an agreement with Novotech Health Holdings (“Novotech”), a leading full-service contract research organization (“CRO”) in Asia-Pacific, for its upcoming Phase 1 study in Australia of its... Read More
Initiation of Phase 1 clinical trial of SBI-100 o phthalmic nanoemulsion expected in the second quarter of 2022 Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye”), a pharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat diseases with significant unmet need, announced that it has completed a good laboratory practice (GLP) nonclinical toxicology study of its SBI-100 ophthalmic nanoemulsion... Read More
Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye”), a pharmaceutical company developing proprietary, synthetic, cannabinoid-derived molecules to treat diseases with significant unmet need, issued today the following letter from Chief Executive Officer and Chair, Punit Dhillon. Dear Shareholders, Colleagues and Collaborators, I would like to thank you for your steadfast support and dedication in bringing our novel cannabinoid-based... Read More
Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye”), a biopharmaceutical company developing proprietary, synthetic, cannabinoid-derived molecules to treat diseases with significant unmet need, announced today that it will present a corporate overview at the H.C. Wainwright BIOCONNECT Conference, held virtually January 10-13, 2022. Punit Dhillon, Chief Executive Officer and Chair, will be presenting an on-demand presentation that... Read More
Skye Bioscience Announces Promotion of Tu Diep, MSc to Chief Development Officer Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need, has appointed Keith W. Ward, PhD, to its board of directors and promoted Tu Diep, MSc to Chief Development Officer, effective... Read More
Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need, announced today researchers from the University of Mississippi presented two Skye-sponsored studies at the 2021 American Association of Pharmaceutical Scientists Meeting (AAPS) PharmSci 360 held October... Read More
Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need, has formed a new exclusive sponsored research agreement with Emerald Health Biotechnology Espana SLU (“EHBE”), focused on developing and characterizing novel molecules that can affect the endocannabinoid... Read More
Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye”), a biopharmaceutical company developing proprietary cannabinoid-derived molecules to treat diseases with significant unmet need, has strengthened its management team with the appointment of Rhea Williams, MPH, as Head of Regulatory Affairs & Quality Assurance and Varun Khurana, PhD, as Senior Director of Research & Development. Rhea Williams, MPH , brings over 25 years of... Read More
Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye”), a biopharmaceutical company developing proprietary cannabinoid-derived molecules to treat diseases with significant unmet need, has appointed Kaitlyn Arsenault, CPA, as Chief Financial Officer. Ms. Arsenault brings over 14 years of experience in accounting, auditing, financial reporting, mergers and acquisitions, as well as business operations in the life science and technology... Read More
Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need, today announced the closing of its previously announced registered direct offering for the purchase and sale of 77,777,779 shares of its common stock (or common stock equivalents in lieu thereof) and... Read More
Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need, today announced that it has entered into securities purchase agreements with several institutional investors, for the purchase and sale in a registered direct offering of 77,777,779 shares of its common... Read More
Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye”), a biopharmaceutical company developing proprietary cannabinoid-derived molecules to treat diseases with significant unmet need, announced today its research partner, the University of Mississippi will present late-breaking preclinical data evaluating different nanoemulsion formulations of its prodrug of tetrahydrocannabinol (THC), THCVHS, in addition to the superiority of THCVHS,... Read More
Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat diseases with significant unmet need, announced today that it will host a special virtual investor presentation on Tuesday, October 12. The filmed broadcast of this virtual event will be available beginning at 1 p.m. ET/10:00 a.m. PT. The agenda will include the company’s... Read More
Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat diseases with significant unmet need, announced today that it will be presenting at the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually from September 13-15, 2021 Punit Dhillon, Chief Executive Officer and Chair, will be presenting an on-demand... Read More
Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat diseases with significant unmet need, announced today that Karam Takhar, VP of Corporate Development and Investor Relations, Skye Bioscience is scheduled to present virtually in the H.C. Wainwright Ophthalmology Conference on Tuesday, August 17 at 7:00 AM ET. Members of the... Read More
THCVHS shows no signs of chromosomal or gene mutations in preclinical studies Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat diseases with significant unmet need, has successfully completed genotoxicity studies of THCVHS required prior to beginning its planned Phase 1 clinical study in Australia. Skye is initially developing... Read More
Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need, has appointed Praveen Tyle, Ph.D., as an independent director to the Company’s board. Dr. Tyle brings over 35 years of experience in the pharmaceutical industry, with over 37 years in senior executive... Read More
Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need, has expanded its Clinical Advisory Board with the appointment of ophthalmology expert and innovator, Miguel González-Andrades, MD, PhD. "We are honored to have Dr. Miguel González-Andrades join our Clinical... Read More
EmergingGrowth.com a leading independent small cap media portal with an extensive history of providing unparalleled content for the Emerging Growth Companies and Markets announces the Schedule of the 9 th Emerging Growth Conference. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall... Read More
THCVHS combined with netarsudil (Rhopressa®) achieves an average maximum intraocular pressure (IOP) reduction of 32.4% and maintains an average IOP reduction of 26.5% at 9 hours, significantly better than any single drug or combination tested THCVHS demonstrates superior IOP-lowering and duration relative to glaucoma standard of care, latanoprost Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a... Read More
Novel glaucoma drug ready for next devel opment phase - GLP toxicology study – on critical path to first human clinical trial Ongoing development of THCVHS includes near-term preclinical comparison with and in combination with leading glaucoma treatments and an assessment of neuroprotecti ve properties Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company developing proprietary, synthetic... Read More
Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need, announced today that Punit Dhillon, CEO, Skye Bioscience will present a virtual corporate overview at the Sequire Cannabis Investor Conference and Planet Microcap Showcase next week. Details are as follows:... Read More
Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need, announced today that Punit Dhillon, CEO, Skye Bioscience will participate in a virtual panel discussion and present a corporate overview at the Benzinga Biotech Small Cap Conference on Thursday, March 25,... Read More
Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need, announced preclinical data demonstrating that THCVHS, the Company’s novel THC prodrug, showed no signs of irritation of the eye using an in vitro assay, the EpiOcular TM MTT ET-50. The EpiOcular TM MTT ET-50... Read More
Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company focused on developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need, announced today the appointment of scientific innovators and cannabinoid experts, Giovanni Appendino, PhD and Eduardo Muñoz, MD, PhD to its scientific advisory board. “We are honored to welcome... Read More
Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company focused on developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need, announced today that Punit Dhillon, CEO, Skye Bioscience will present a corporate overview at the H.C. Wainwright Global Life Sciences Conference on Tuesday, March 09, 2021. Mr. Dhillon will also... Read More
Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company focused on developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need, announced that members of its leadership team will present at several upcoming investment events in February, including the Small-Cap Growth Investor Conference, the Money Show February Virtual... Read More

COPYRIGHT ©2022 GREEN STOCK NEWS